Compare stocks

Innate Pharma S.A. is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on developing therapeutic antibodies that engage the innate immune system to treat cancer. Its pipeline includes lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous and peripheral T-cell lymphomas, and monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, the company has established collaborations with biopharmaceutical firms such as AstraZeneca and Sanofi. Innate Pharma's proprietary ANKET® platform focuses on developing multi-specific NK cell engagers, positioning the company in the field of natural killer cell therapeutics.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.